NYSE:WAT - Waters Stock Price, Price Target & More

Waters trades on the New York Stock Exchange (NYSE) under the ticker symbol "WAT."

Waters declared that its Board of Directors has authorized a share repurchase program on Tuesday, April 24th 2018, which permits the company to repurchase $3,000,000,000.00 in shares, according to EventVestor. This repurchase authorization permits the company to buy up to 18.2% of its stock through open market purchases. Stock repurchase programs are typically an indication that the company's board believes its stock is undervalued.

Waters Co. (NYSE:WAT) issued its quarterly earnings results on Tuesday, April, 24th. The medical instruments supplier reported $1.59 EPS for the quarter, topping the Thomson Reuters' consensus estimate of $1.55 by $0.04. The medical instruments supplier had revenue of $530.70 million for the quarter, compared to analyst estimates of $534.17 million. Waters had a net margin of 1.14% and a return on equity of 25.80%. The business's revenue for the quarter was up 6.6% on a year-over-year basis. During the same period in the prior year, the firm earned $1.46 EPS. View Waters' Earnings History.

Waters is scheduled to release their next quarterly earnings announcement on Tuesday, July, 24th 2018. View Earnings Estimates for Waters.

Waters issued an update on its FY18 earnings guidance on Tuesday, April, 24th. The company provided earnings per share guidance of $8.10-8.30 for the period, compared to the Thomson Reuters consensus EPS estimate of $8.19.

17 brokerages have issued twelve-month target prices for Waters' stock. Their predictions range from $180.00 to $230.00. On average, they expect Waters' stock price to reach $206.5333 in the next year. View Analyst Ratings for Waters.

Some companies that are related to Waters include Illumina (ILMN), Agilent Technologies (A), Mettler-Toledo International (MTD), Bio-Rad Laboratories, Inc. Class A Common Stock (BIO), Bio-Rad Laboratories, Inc. Class B (BIO.B), PerkinElmer (PKI), Integra Lifesciences (IART), Bruker (BRKR), Coherent (COHR), Horiba (HRIBF), Accelerate Diagnostics (AXDX), Pacific Biosciences of California (PACB), Quanterix (QTRX), Fluidigm (FLDM) and Harvard Bioscience (HBIO).

Media stories about WAT stock have been trending somewhat positive recently, according to Accern Sentiment. Accern scores the sentiment of news coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Waters earned a media sentiment score of 0.03 on Accern's scale. They also gave news stories about the medical instruments supplier an impact score of 43.84 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company's share price in the near term.

Waters' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (7.20%), Massachusetts Financial Services Co. MA (6.33%), Baillie Gifford & Co. (3.29%), Veritas Asset Management LLP (2.50%), Northern Trust Corp (1.38%) and Franklin Resources Inc. (1.14%). Company insiders that own Waters stock include Arthur G Caputo, Christopher A Kuebler, David Terricciano, Elizabeth B Rae, Eugene G Cassis, Ian King, Joann A Reed, Laurie H MD Glimcher, Mark T Beaudouin, Michael C Harrington, Michael F Silveira, Michael J Berendt, Rohit Khanna, Terrence P Kelly, Thomas P Salice and William J Miller. View Institutional Ownership Trends for Waters.

WAT stock was sold by a variety of institutional investors in the last quarter, including Massachusetts Financial Services Co. MA, Veritas Asset Management LLP, Baillie Gifford & Co., Schroder Investment Management Group, Boston Partners, Millennium Management LLC, Swiss National Bank and American Century Companies Inc.. Company insiders that have sold Waters company stock in the last year include Christopher A Kuebler, David Terricciano, Elizabeth B Rae, Eugene G Cassis, Joann A Reed, Mark T Beaudouin, Michael C Harrington, Michael F Silveira, Rohit Khanna, Terrence P Kelly, Thomas P Salice and William J Miller. View Insider Buying and Selling for Waters.

WAT stock was purchased by a variety of institutional investors in the last quarter, including Frontier Capital Management Co. LLC, Citigroup Inc., Bamco Inc. NY, Summit Trail Advisors LLC, JPMorgan Chase & Co., Royal Bank of Canada, Ontario Teachers Pension Plan Board and Champlain Investment Partners LLC. View Insider Buying and Selling for Waters.

Shares of WAT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of WAT stock can currently be purchased for approximately $194.19.

Waters has a market capitalization of $15.12 billion and generates $2.31 billion in revenue each year. The medical instruments supplier earns $20.31 million in net income (profit) each year or $7.49 on an earnings per share basis. Waters employs 7,000 workers across the globe.

Waters' mailing address is 34 MAPLE STREET, MILFORD MA, 01757. The medical instruments supplier can be reached via phone at 508-478-2000 or via email at [email protected]